Tracers / [153Sm]Sm-EDTMP
[153Sm]Sm-EDTMP
Also written as Sm-153-EDTMP; [Sm-153]EDTMP
- Radionuclide
- Sm-153 t½ 2776.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- approved
- Syntheses indexed
- 10
What it is
- Compound class
- 153Sm-EDTMP (bone-seeking bisphosphonate radiopharmaceutical)
- Target / mechanism
- Bone hydroxyapatite (bone mineral matrix) PMID 34001824
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | enriched 152Sm targets | 35939938 2022 Appl Radiat Isot |
| — | — | — | — | — | — | 34001824 2021 Nucl Med Commun |
| — | — | — | — | — | 152Sm | 29309920 2018 Nucl Med Biol A radiochemical separation procedure adopting electroamalgamation approach has been critically evaluated. |
| — | — | — | ~98% | — | 152Sm | 21510750 2011 Cancer Biother Radiopharm They were labeled with EDTMP at varying degrees of pH and molar ratios, and labeling yields were determined by paper chromatography at each data point. — All the four radiopharmaceuticals gave ∼98% complex yields at pH 8. |
| — | — | — | — | — | — | 18751975 2009 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 16416330 2006 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 12123545 2002 Chin Med J (Engl) |
| — | — | — | — | — | — | 11797510 2001 Nuklearmedizin |
| — | — | — | — | — | — | 9933654 1999 Eur J Nucl Med |
| — | — | — | — | 96.9 +/- 1.7% | EDTMP | 8358352 1993 Nucl Med Biol |
Need this precursor?We can point you to suppliers for [153Sm]Sm-EDTMP, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 15 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.